The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Ostroumova O.D.

Kafedra fakul'tetskoĭ terapii i professional'nykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta im. A.I. Evdokimova, Moskva

Cherniaeva M.S.

Central State Medical Academy of Department of Presidential Affairs, Moscow, Russia

Arterial hypertension, cognitive disorders and dementia: a view of a cardiologist

Authors:

Ostroumova O.D., Cherniaeva M.S.

More about the authors

Read: 4628 times


To cite this article:

Ostroumova OD, Cherniaeva MS. Arterial hypertension, cognitive disorders and dementia: a view of a cardiologist. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(9):117‑125. (In Russ.)
https://doi.org/10.17116/jnevro2018118091117

Recommended articles:
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
The possibilities of Mexi­dol in the complex therapy of arte­rial hype­rtension. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):572-580
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146

References:

  1. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial. Russian Journal of Cardiology. 2014;19(1):7-94. (In Russ.)
  2. Chazova IE, Oschepkova EV. Results of the Federal (National) Project for prevention and treatment essential hypertension patients in Russia from 2002—2012 years. Vestnik Rossiiskoi akademii meditsinskikh nauk. 2013;2:4-11. (In Russ.)
  3. Boytsov SA, Balanova YuA, Shalnova SA, Deev AD, Artamonova GV, Gatagonova TM, Duplyakov DV, Efanov AYu, Zhernakova YuV, Konradi AO, Libis RA, Minakov AV, Nedogoda SV, Oshchepkova EV, Romanchuk SV, Rotar OP, Trubacheva IA, Chazova IE, Shlyakhto EV, Karpov RS, Kaveshnikov VS, Serebryakova VN, Muromtseva GA, Evstifeeva SE, Kapustina AV, Konstantinov VV, Oganov RG, Mamedov MN, Nazarova OA, Shutemova EA, Babenko NI, Furmenko GI, Bondartsov LV, Ledyaeva AA, Chumachek EV, Isaeva EN, Basyrova IR, Lopina EA, Safonova DV, Skripchenko AE, Indukaeva EV, Cherkass NV, Maksimov SA, Danilchenko YaV, Mulerova TA, Shalaev SV, Medvedeva IV, Shava VP, Storozhok MA, Tolparov GV, Astakhova ZT, Toguzova ZA. Arterial hypertension among individuals of 25—64 years old: prevalence, awareness, treatment and control. By the data from ECCD. Cardiovascular Therapy and Prevention. 2014;13(4):4-14. (In Russ.) https://doi.org/10.15829/1728-8800-2014-4-4-14
  4. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp-Pedersen C, Hildebrandt P, Olsen MH. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. European Heart Journal. 2010;31(7):883-891. https://doi.org/10.1093/eurheartj/ehp546
  5. Sehestedt T, Jeppesen J, Hansen TW, Rasmussen S, Wachtell K, Ibsen H, Torp-Pedersen C, Olsen MH. Thresholds for pulse wave velocity, urine albumin creatinine ratio and left ventricular mass index using SCORE, Framingham and ESH/ESC risk charts. Journal of Hypertension. 2012;30(10):1928-1936. https://doi.org/10.1097/HJH.0b013e328356c579
  6. Volpe M, Battistoni A, Tocci G, Agabiti Rosei E, Catapano AL, Coppo R, del Prato S, Gentile S, Mannarino E, Novo S, Prisco D, Mancia G. Cardiovascular risk assessment beyond systemic coronary risk estimation: a role for organ damage markers. Journal of Hypertension. 2012;30(6):1056-1064. https://doi.org/10.1097/HJH.0b013e3283525715
  7. Kearney-Schwartz A, Rossignol P, Bracard S, Felblinger J, Fay R, Boivin JM, Lecompte T, Lacolley P, Benetos A, Zannad F. Vascular structure and function is correlated to cognitive performance and white matter hyperintensities in older hypertensive patients with subjective memory complaints. Stroke. 2009;40(4):1229-1236. https://doi.org/10.1161/STROKEAHA.108.532853
  8. Longstreth WT Jr, Manolio TA, Arnold A, Burke GL, Bryan N, Jungreis CA, Enright PL, O’Leary D, Fried L. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. The Cardiovascular Health Study. Stroke. 1996;27(8):1274-1282.
  9. de Leeuw FE, de Groot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, Breteler MM. Hypertension and cerebral white matter lesions in a prospective cohort study. Brain. 2002;125(4):765-772.
  10. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet. Neurology. 2007;6(7):611-619. https://doi.org/10.1016/S1474-4422(07)70170-9
  11. Wong TY, Klein R, Sharrett AR, Couper DJ, Klein BE, Liao DP, Hubbard LD, Mosley TH. Cerebral white matter lesions, retinopathy and incident clinical stroke. JAMA. 2002;288(1):67-74.
  12. Buyck JF, Dufouil C, Mazoyer B, Maillard P, Ducimetiere P, Alperovitch A, Bousser MG, Kurth T, Tzourio C. Cerebral white matter lesions are associated with the risk of stroke but not with other vascular events: the 3-City Dijon Study. Stroke. 2009;40(7):2327-2331. https://doi.org/10.1161/STROKEAHA.109.548222
  13. Zakharov VV. Cognitive Impairment no Dementia: Classification, Major Causes, and Treatment. Effektivnaya farmakoterapiya. Nevrologiya i psihiatriya. 2016;1:22-30. (In Russ.)
  14. Yahno NN, Zaharov VV, Lokshina AB, Koberskaya NN, Mhitaryan EA. Dementia: guidelines for doctors. M.: MED press-inform; 2011. (In Russ.)
  15. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;429(9):2672-2713. https://doi.org/10.1161/STR.0b013e3182299496
  16. Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J, Kanba S, Iwaki T, Kiyohara Y. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension. 2011;58(1):22-28. https://doi.org/10.1161/HYPERTENSIONAHA.110.163055
  17. Iadecola C, Yaffe K, Biller J, Bratzke LC, Faraci FM, Gorelick PB, Gulati M, Kamel H, Knopman DS, Launer LJ, Saczynski JS, Seshadri S, Zeki Al Hazzouri A. Impact of Hypertension on Cognitive Function A Scientific Statement From the American Heart Association. Hypertension. 2016;68(6):67-94. https://doi.org/10.1161/HYP.0000000000000053
  18. Cerhan JR, Folsom AR, Mortimer JA, Shahar E, Knopman DS, McGovern PG, Hays MA, Crum LD, Heiss G. Correlates of cognitive function in middle-aged adults: Atherosclerosis Risk in Communities (ARIC) Study Investigators. Gerontology. 1998;44(2):95-105. https://doi.org/10.1159/000021991
  19. Starr JM, Whalley LJ, Inch S, Shering PA. Blood pressure and cognitive function in healthy old people. Journal of the American Geriatrics Society. 1993;41(7):753-756.
  20. Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension. 1998;31(3):780-786.
  21. Kuo HK, Sorond F, Iloputaife I, Gagnon M, Milberg W, Lipsitz LA. Effect of blood pressure on cognitive functions in elderly persons. The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 2004;59(11):1191-1194.
  22. Obisesan TO, Obisesan OA, Martins S, Alamgir L, Bond V, Maxwell C, Gillum RF. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. Journal of the American Geriatrics Society. 2008;56(3):501-509. https://doi.org/10.1111/j.1532-5415.2007.01592.x
  23. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia Aging Study. JAMA. 1995;274(23):1846-1851.
  24. Guo Z, Fratiglioni L, Winblad B, Viitanen M. Blood pressure and performance on the Mini-Mental State Examination in the very old: cross-sectional and longitudinal data from the Kungsholmen Project. American Journal of Epidemiology. 1997;145(12):1106-1113.
  25. Waldstein SR, Giggey PP, Thayer JF, Zonderman AB. Nonlinear relations of blood pressure to cognitive function: the Baltimore Longitudinal Study of Aging. Hypertension. 2005;45(3):374-379. https://doi.org/10.1161/01.HYP.0000156744.44218.74
  26. Farmer ME, White LR, Abbott RD, Kittner SJ, Kaplan E, Wolz MM, Brody JA, Wolf PA. Blood pressure and cognitive performance: the Framingham Study. Am J Epidemiol. 1987;126:1103-1114.
  27. Richmond R, Law J, Kay-Lambkin F. Higher blood pressure associated with higher cognition and functionality among centenarians in Australia. American Journal of Hypertension. 2011;24(3):299-303. https://doi.org/10.1038/ajh.2010.236
  28. Peltz CB, Corrada MM, Berlau DJ, Kawas CH. Cognitive impairment in nondemented oldest-old: prevalence and relationship to cardiovascular risk factors. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2012;8(2):87-94. https://doi.org/10.1016/j.jalz.2011.02.008
  29. Kritz-Silverstein D, Laughlin GA, McEvoy LK, Barrett-Connor E. Sex and Age Differences in the Association of Blood Pressure and Hypertension with Cognitive Function in the Elderly: The Rancho Bernardo Study. The Journal of Prevention of Alzheimer’s Disease. 2017;4(3):165-173. https://doi.org/10.14283/jpad.2017.6
  30. Shang S, Li P, Deng M, Jiang Y, Chen C, Qu Q. The Age-Dependent Relationship between Blood Pressure and Cognitive Impairment: A Cross-Sectional Study in a Rural Area of Xi’an, China. PLoS One. 2016;11(7):e0159485. https://doi.org/10.1371/journal.pone.0159485
  31. Hebert LE, Scherr PA, Bennett DA, Bienias JL, Wilson RS, Morris MC, Evans DA. Blood pressure and late-life cognitive function change: a biracial longitudinal population study. Neurology. 2004;62(11):2021-2024.
  32. Solfrizzi V, Panza F, Colacicco AM, D’Introno A, Capurso C, Torres F, Grigoletto F, Maggi S, Del Parigi A, Reiman EM, Caselli RJ, Scafato E, Farchi G, Capurso A. Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004;63(10):1882-1891.
  33. Yaffe K, Haan M, Blackwell T, Cherkasova E, Whitmer RA, West N. Metabolic syndrome and cognitive decline in elderly Latinos: findings from the Sacramento Area Latino Study of Aging study. Journal of the American Geriatrics Society. 2007;55(5):758-762. https://doi.org/10.1111/j.1532-5415.2007.01139.x
  34. Johnson KC, Margolis KL, Espeland MA, Colenda CC, Fillit H, Manson JE, Masaki KH, Mouton CP, Prineas R, Robinson JG, Wassertheil-Smoller S. A prospective study of the effect of hypertension and baseline blood pressure on cognitive decline and dementia in postmenopausal women: the Women’s Health Initiative Memory Study. Journal of the American Geriatrics Society. 2008;56(8):1449-1458. https://doi.org/10.1111/j.1532-5415.2008.01806.x
  35. Bohannon AD, Fillenbaum GG, Pieper CF, Hanlon JT, Blazer DG. Relationship of race/ethnicity and blood pressure to change in cognitive function. Journal of the American Geriatrics Society. 2002;50(3):424-429.
  36. Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, McGovern P, Folsom AR. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology. 2001;56(1):42-48.
  37. Dregan A, Stewart R, Gulliford MC. Cardiovascular risk factors and cognitive decline in adults aged 50 and over: a population-based cohort study. Age Ageing. 2013;42(3):338-345. https://doi.org/10.1093/ageing/afs166
  38. Yasar S, Ko JY, Nothelle S, Mielke MM, Carlson MC. Evaluation of the effect of systolic blood pressure and pulse pressure on cognitive function: the Women’s Health and Aging Study II. PLoS One. 2011;6(12):e27976. https://doi.org/10.1371/journal.pone.0027976
  39. van Vliet P, Westendorp RG, van Heemst D, de Craen AJ, Oleksik AM. Cognitive decline precedes late-life longitudinal changes in vascular risk factors. Journal of Neurology, Neurosurgery, and Psychiatry. 2010;81(9):1028-1032. https://doi.org/10.1136/jnnp.2009.182519
  40. Euser SM, van Bemmel T, Schram MT, Gussekloo J, Hofman A, Westendorp RG, Breteler MM. The effect of age on the association between blood pressure and cognitive function later in life. Journal of the American Geriatrics Society. 2009;57(7):1232-1237. https://doi.org/10.1111/j.1532-5415.2009.02264.x
  41. Sabayan B, Oleksik AM, Maier AB, van Buchem MA, Poortvliet RK, de Ruijter W, Gussekloo J, de Craen AJ, Westendorp RG. High blood pressure and resilience to physical and cognitive decline in the oldest old: the Leiden 85-plus Study. Journal of the American Geriatrics Society. 2012;60(11):2014-2019. https://doi.org/10.1111/j.1532-5415.2012.04203.x
  42. Harrison SL, Stephan BC, Siervo M, Granic A, Davies K, Wesnes KA, Kirkwood TB, Robinson L, Jagger C. Is there an association between metabolic syndrome and cognitive function in very old adults? The Newcastle 85+ Study. Journal of the American Geriatrics Society. 2015;63(4):667-675. https://doi.org/10.1111/jgs.13358
  43. Lacruz ME, Tiller D, Kluttig A, Greiser KH, Nuding S, Werdan K, Haerting J. Lacruz Association of late-life changes in blood pressure and cognitive status. Journal of Geriatric Cardiology. 2016;13(1):37-43. https://doi.org/10.11909/j.issn.1671-5411.2016.01.018
  44. Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, Ohmori S, Nomiyama K, Kawano H, Ueda K, Sueishi K, Tsuneyoshi M, Fujishima M. Incidence and risk factors of vascular dementia and Alzheimer’s disease in a defined elderly Japanese population: the Hisayama Study. Neurology. 1995;45(6):1161-1168.
  45. Oveisgharan S, Hachinski V. Hypertension, executive dysfunction, and progression to dementia: the Canadian Study of Health and Aging. Archives of Neurology. 2010;67(2):187-192. https://doi.org/10.1001/archneurol.2009.312
  46. Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R. The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function. Neurology. 2002;5(8):1175-1181.
  47. Qiu C, von Strauss E, Fastbom J, Winblad B, Fratiglioni L. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Archives of Neurology.2003;60(2):223-228.
  48. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, Persson G, Odén A, Svanborg A. 15-Year longitudinal study of blood pressure and dementia. Lancet. 1996;347(9009):1141-1145.
  49. Ruitenberg A, Skoog I, Ott A, Aevarsson O, Witteman JC, Lernfelt B, van Harskamp F, Hofman A, Breteler MM. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dementia and Geriatric Cognitive Disorders. 2001;12(1):33-39. https://doi.org/10.1159/000051233
  50. Qiu C, von Strauss E, Winblad B, Fratiglioni L. Decline in blood pressure over time and risk of dementia: a longitudinal study from the Kungsholmen project. Stroke. 2004;35(8):1810-1815. https://doi.org/10.1161/01.STR.0000133128.42462.ef
  51. Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ. Clinical risk factors for Alzheimer’s disease: a population-based case-control study. Neurology. 1991;41(9):1393-1397.
  52. Verghese J, Lipton RB, Hall CB, Kuslansky G, Katz MJ. Low blood pressure and the risk of dementia in very old individuals. Neurology. 2003;61(12):1667-1672.
  53. Kivipelto M, Helkala EL, Hänninen T, Laakso MP, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology. 2001;56(12):1683-1689. https://doi.org/10.1212/WNL.56.12.1683
  54. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A. Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population based study. BMJ. 2001;322(7300):1447-1451. https://doi.org/10.1136/bmj.322.7300.1447
  55. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-281. https://doi.org/10.1212/01.WNL.0000149519.47454.F2
  56. Launer LJ, Ross GW, Petrovitch H, Masaki K, Foley D, White LR, Havlik RJ. Midlife blood pressure and dementia: the Honolulu-Asia Aging Study. Neurobiology of Aging. 2000;21(1):49-55.
  57. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. Journal of Hypertension. 2003;21(6):1011-1053. https://doi.org/10.1097/01.hjh.0000059051.65882.32
  58. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Erdine S, Kiowski W, Agabiti-Rosei E, Ambrosioni E, Lindholm LH, Viigimaa M, Adamopoulos S, Agabiti-Rosei E, Ambrosioni E, Bertomeu V, Clement D, Erdine S, Farsang C, Gaita D, Lip G, Mallion JM, Manolis AJ, Nilsson PM, O’Brien E, Ponikowski P, Redon J, Ruschitzka F, Tamargo J, van Zwieten P, Waeber B, Williams B. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH ) and of the European Society of Cardiology (ESC). Journal of Hypertension. 2007;25(6):1105-1187. https://doi.org/10.1097/HJH.0b013e3281fc975a
  59. Aronow WS, Fleg JL, Pepine CJ, Artinian NT, Bakris G, Brown AS, Ferdinand KC, Ann Forciea M, Frishman WH, Jaigobin C, Kostis JB, Mancia G, Oparil S, Ortiz E, Reisin E, Rich MW, Schocken DD, Weber MA, Wesley DJ. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists and European Society of Hypertension. Journal of the American College of Cardiology. 2011;57(20):2037-2114. https://doi.org/10.1016/j.jacc.2011.01.008
  60. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, van Zwieten PA, Viigimaa M, Zanchetti A. Re-appraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension. 2009;27(11):2121-2158. https://doi.org/10.1097/HJH.0b013e328333146d
  61. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical re-appraisal. Journal of Hypertension. 2009;27(5):923-934. https://doi.org/10.1097/HJH.0b013e32832aa6b5
  62. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, Banya W, Bulpitt CJ. Treatment of hypertension in patients 80 years of age or older. New England Journal of Medicine. 2008;358(18):1887-1898. https://doi.org/10.1056/NEJMoa0801369
  63. JATOS Study Group. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertension Research. 2008;31(12):2115-2127. https://doi.org/10.1291/hypres.31.2115
  64. Ogihara T, Saruta T, Rakugi H, Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Hypertension. 2010;56(2):196-202. https://doi.org/10.1161/HYPERTENSIONAHA.109.146035
  65. Zhang Y, Zhang X, Liu L, Zanchetti A. Is a systolic blood pressure target <140mmHg indicated in all hypertensives? Subgroup analyses of findings from the randomized FEVER trial. European Heart Journal. 2011;32(12):1500-1508. https://doi.org/10.1093/eurheartj/ehr039
  66. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991;265(24):3255-3264.
  67. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet. 1991;338(8778):1281-1285.
  68. Amery A, Birkenhager W, Brixko P, Bulpitt C, Clement D, Deruyttere M, De Schaepdryver A, Dollery C, Fagard R, Forette F. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1(8442):1349-1354.
  69. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304(6824):405-412.
  70. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ. 1986;293(6555):1145-1151.
  71. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O’Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-764.
  72. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic Hypertension in China (Syst-China) Collaborative Group. Journal of Hypertension. 1998;16(12 Pt1):1823-1829.
  73. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, de Faire U. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354(9192):1751-1756.
  74. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, Trenkwalder P, Zanchetti A. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized doubleblind intervention trial. Journal of Hypertension. 2003;21(5):875-886. https://doi.org/10.1097/01.hjh.0000059028.82022.89
  75. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, Barzi F, Bulpitt C, Chalmers J, Fagard R, Gleason A, Heritier S, Li N, Perkovic V, Woodward M, MacMahon S. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: metaanalysis of randomized trials. BMJ. 2008;336(7653):1121-1123. https://doi.org/10.1136/bmj.39548.738368.BE
  76. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, Waldman A, Walton I, Poulter R, Ma S, Comsa M, Burch L, Fletcher A, Bulpitt C. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVETCOG): a double-blind, placebo controlled trial. Lancet. Neurology. 2008;7(8):683-689. https://doi.org/10.1016/S1474-4422(08)70143-1
  77. Dufouil C, Godin O, Chalmers J, Coskun O, McMahon S, Tzourio-Mazoyer N, Tzourio C. Severe cerebral white matter hypersensities predict severe cognitive decline in patients with cerebrovascular disease history. Stroke. 2009;40(6):2219-2221. https://doi.org/10.1161/STROKEAHA.108.540633
  78. Godin O, Tsourio C, Maillard P, Mazoyer B, Dufouil C. Antihypertensive treatment and change in blood pressure are associated with the progression of white matter lesion volumes: the Three-City (3C) — Dijon Magnetic Resonance Imaging Study. Circulation. 2011;123(3):266-273. https://doi.org/10.1161/CIRCULATIONAHA.110.961052
  79. Tadic M, Cuspidi C, Hering D. Hypertension and cognitive dysfunction in elderly: blood pressure management for this global burden. BMC Cardiovascular Disorders. 2016;16(1):208. https://doi.org/10.1186/s12872-016-0386-0
  80. Rouch L, Cestac P, Hanon O, Cool C, Helmer C, Bouhanick B, Chamontin B, Dartigues JF, Vellas B, Andrieu S. Antihypertensive drugs, prevention of cognitive decline and dementia: a systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms. CNS Drugs. 2015;29(2):113-130. https://doi.org/10.1007/s40263-015-0230-6
  81. Gasowski J, Staessen JA, Celis H, Fagard RH, Thijs L, Birkenhäger WH, Bulpitt CJ, Fletcher AE, Arabidze GG, de Leeuw P, Dollery CT, Duggan J, Kawecka-Jaszcz K, Leonetti G, Nachev C, Safar M, Rodico JL, Rosenfeld J, Seux ML, Tuomilehto J, Webster J, Yodfat Y. Systolic Hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol, and initial progress. Systolic Hypertension in Europe Investigators. Journal of Human Hypertension. 1999;13(2):135-145.
  82. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). Journal of the Renin-Angiotensin-Aldosterone System. 2000;1(1):18-20. https://doi.org/10.3317/jraas.2000.002
  83. Arima H, Chalmers J. PROGRESS: Prevention of Recurrent Stroke. Journal of clinical hypertension (Greenwich, Conn.). 2011;13(9):693-702. https://doi.org/10.1111/j.1751-7176.2011.00530.x
  84. Hernandorena I, Duron E, Vidal JS, Hanon O. Treatment options and considerations for hypertensive patients to prevent dementia. Expert Opinion on Pharmacotherapy. 2017;18(10):989-1000. https://doi.org/10.1080/14656566.2017.1333599
  85. Hajjar I, Rosenberger KJ, Kulshreshtha A, Ayonayon HN, Yaffe K, Goldstein FC. Association of JNC-8 and SPRINT Systolic Blood Pressure Levels With Cognitive Function and Related Racial Disparity. JAMA Neurology. 2017;74(10):1199-1205. https://doi.org/10.1001/jamaneurol.2017.1863
  86. Piradov MA, Tanashyan MM, Domashenko MA, Maksimova MYu. Neuroprotection in cerebrovascular diseases: is it the search for life on Mars or a promising trend of treatment? Part 2. Chronic cerebrovascular diseases. Annaly klinicheskoy i eksperimental’noy nevrologii. 2015;9(3):10-19. (In Russ.)
  87. Drozdova TV, Fitmova OA, Fitmova AA. Role of mexidol in the therapy of mild cognitive impairment in chronic cerebrovascular insufficiency. Pharmateca. 2012;14:97-103. (In Russ.)
  88. Damulin IV. Cognitive Impairment In Cerebrovascular Diseases: Some Aspects Of Diagnosis And Treatment. Pharmateca. 2011;19:30-35. (In Russ.)
  89. Smirnova IN, Fyodorova TN, Tanashyan MM, Suslina ZA. Clinical effect and antioxidant activity of Mexidol in chronic cerebrovascular diseases. Atmosfera. Nervnye bolezni. 2006;1:33-36. (In Russ.)
  90. Teleshova ES, Davydova IA, Neznamov GG. The use of mexidol in patients with organic diseases of the brain. Psihiatriya i psihofarmakoterapiya im. P.B. Gannushkina. 2009;11(6):29-33. (In Russ.)
  91. Kosenko VG, Karagezyan EA, Luneva LV, Smolenko L. The use of mexidol in psychiatric practice. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2006;106(6):38-41. (In Russ.)
  92. Chukanova EI, Chukanova AS, Mamaeva KhI. The results of the study of the efficacy and safety of mexidol in patients with chronic cerebral ischemia. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2015;115(2-1):71-74. (In Russ.)

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.